Wasting syndrome in cancer patients: Pathophysiology, clinical manifestations and drug therapy;El síndrome caquéctico en el paciente oncológico: Fisiopatología, manifestaciones clínicas y tratamiento farmacológico

Farmacia Hospitalaria

Volumn 27, Issue 5, 2003, Pages 308-316

  Ferriols Lisart, Francisco ^a   Tordera Baviera, M ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Clinical manifestations; Drug therapy; Pathophysiology; Wasting

Indexed keywords

AMINOGLUTETHIMIDE; ANABOLIC AGENT; ANTACID AGENT; ANTICOAGULANT AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CIMETIDINE; CIPROFLOXACIN; CISAPRIDE; CORTICOSTEROID; CYPROHEPTADINE; DRONABINOL; EPHEDRINE; FLUVOXAMINE; GESTAGEN; HYDRAZINE; MEGESTROL ACETATE; MELATONIN; NIFEDIPINE; OXANDROLONE; PENTOXIFYLLINE; PIZOTIFEN; PROCAINAMIDE; SEROTONIN ANTAGONIST; THALIDOMIDE;

ANOREXIA; CANCER PATIENT; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; INCREASED APPETITE; LUNG EMBOLISM; NUTRITIONAL SUPPORT; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; SOMNOLENCE; TACHYCARDIA; WASTING SYNDROME;

HUMANS; NEOPLASMS; WASTING SYNDROME;

EID: 0142011529     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Bristian B. Dietary treatment in secondary wasting and cachexia. The Journal of Nutrition 1999; 129 (1): 290S-4S.
2. Heber D, Tchekmedyian NS. Mechanisms of cancer cachexia. Contemporary Oncology 1995; March: 6-10.
3. Langstein HN, Norton JA. Mechanisms of cancer cachexia. Hematol Oncol Clin North Am 1999; 15: 103-23.
4. Cuerda MC, Bretón I, Camblor M, García P. Modulación farmacológica del apetito. Nutrición Hospitalaria 1998; 13 (2): 69-75.
5. Montovani G, Macciò A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine activity in cancer related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Seminars in Oncology 1998; 25 (2 Supl. 6): 45-52.
6. Haslett P. Anticytokine approaches to the treatment of anorexia and cachexia. Seminars in Oncology 1998; 25 (2): 53-7.
7. Von Roenn JH, Knopf K. Anorexia/cachexia in patients with HIV: lessons for the oncologist. Oncology 1996; 10: 1049-56.
8. Ottery FD. Supportive nutrition to prevent cachexia and improve quality of life. Semin Oncol 1995; 22 (Supl. 13): 98-111.
9. Jacobsen PB, Scwartz M. Food aversions during cancer therapy: Incidence, etiology, and prevention. Oncology 1993; 7 (Supl. 11): 139-44.
10. Ottery F, Walsh D, Strawford A. Pharmacologic management of anorexia/cachexia. Seminars in Oncology 1998; 25 (2): 35-44.
11. Catálogo de Especialidades Farmacéuticas 2001. Ed. Consejo General de Colegios Oficiales de Farmacéuticos. Madrid, 2001.
12. Porter AC, Felder CC. The endocannabinoid nervous system: unique opportunities for theraapeutic intervnetion. Pharmacol Ther 2001; 90 (1): 45-60.
13. Seligman P, Fink R, Massey-Seligman E. Approach to the seriously ill or terminal cancer patient who has a poor appetite. Seminars in Oncology 1998; 25 (2 Supl. 6): 33-4.
14. Popiela T, Lucchi R, Gingo F. Methylprdenisolone as palliative therapy for female terminal cancer patients. Eur J cancer Clin Oncol 1989; 25: 1819-21.
15. Puccio M, Nathanson L. The cancer cachexia syndrome. Seminars in Oncology 1997; 24 (3): 277-87.
16. Mann M. Approved pharmacologic interventions for wasting: an overview and lessons learned. The Journal of Nutrition 1999; 129 (1): 303S-5S.
17. Jatoi A, Kumar S, Sloan J, Nguyen P. On appetite and its loss. Journal of Clinical Oncolgy 2000; 18 (15): 2930-2.
18. Macallan D. Wasting in HIV infection and AIDS. The Journal of nutrition 1999; 129 (1): 238S-42S.
19. Nandrolona. DrugDex© Drug Evaluation. En: Micromedex Healthcare Series 1974-2002 (Vol 111). http://www.micromedex.com
20. Baum HB, Biller B, Finkelstein J. Effects of physiologic growth hormone therapy on bone density and body compositionb in patients with adult onset growth hormone deficiency: a randomized place-controlled trial. Ann Intern Med 1996; 125: 883-90.
21. Chlebowski RT, Bulcavage L, Grovesnor M. Hydrazine sulfate influence on nutritional status and survival in non small cell lung cancer. J Clin Oncol 1990; 8: 9-15.
22. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998; 55 (5): 675-88.
23. Dezube BJ, Pardee AB, Chapman B. Pentoxifyline decreases tumor necrosis factor expression and seum triglycerides in people with AIDS. J AIDS 1993: 6-19.
24. Talidomida DrugDex® Drug Evaluation. En: Micromedex Healthcare Series 1974-2002 (Vol 111). http://www.micromedex.com
25. Lissoni P, Paolorosssi F, Tancini G. Is there a rtole for melatonin in the treatment of neoplastic cachexia. Eur J Cancer 1996; A: 1340-3.